|The CHGA chga (Catalog #MBS646665) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Catestatin reacts with Human, Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s Catestatin can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC).
Suitable for use in Immunohistochemistry.
Dilution: Immunohistochemistry (formalin-fixed paraffin): 1:500 (DAB). Researchers should empirically determine the suitability of the CHGA chga for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CHGA chga product has the following accession number(s) (GI #4502805) (NCBI Accession #NP_001266.1) (Uniprot Accession #P10645). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide that is formed endogenously by proteolytic cleavage of its precursor chromogranin A, a major protein co-stored and co-released with catecholamines from the storage vesicles in adrenal chromaffin cells and adrenergic neurons. This peptide exhibits potent catecholamine release-inhibitory activity by acting on the neuronal nicotinic acetylcholine receptor. It also stimulates histamine release from mast cells via heterotrimeric G-proteins in a receptor-independent manner. Plasma levels of catestatin are diminished not only in hypertensive patients but also in their still-normotensive offspring, indicating its role in the pathogenesis of hypertension. Consistently, exogenous catestatin rescues hypertension in chromogranin A knockout mice and diminishes blood pressure responses to activation of sympathetic outflow in rats. These hypotensive actions of catestatin may be caused directly by autocrine inhibition of catecholamine release from the sympathoadrenal system and indirectly by paracrine stimulation of the potent vasodilator histamine release from mast cells. Recently, three human variants of catestatin displaying differential potencies for inhibition of catecholamine secretion have been identified. One of these variants (Gly364Ser) causes increased baroreceptor sensitivity, increased cardiac parasympathetic activity, and decreased cardiac sympathetic activity, and it seems to alter the risk for hypertension. These cardiovascular effects may have resulted by action of this peptide in the baroreceptor centre of the nucleus tractus solitarius. Thus, accumulating evidence documents the endogenous peptide catestatin as a novel regulator of cardiac function and blood pressure.
Immunogen: Synthetic peptide corresponding to mouse Catestatin. Positive Control: Human pancreas tissue. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CHGA are readily searchable from our website. Different antibodies against the same target such as CHGA may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.